Clinical Trials Browser

Phase 1/2 × Capsules × Other hematologic neoplasm × Clear all

NCT02629692 2024-07-31

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Phase 1/2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive